Flanagan AM, Larousserie F, O'Donnell P, Yoshida A (2020) Giant cell tumour of bone. In: the WHO Classification of Tumours Editorial Board (ed) WHO classification of tumours: soft tissue and bone tumours. 5th edition. IARC, Lyon, pp. 440–446

Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45:1479–1482. https://doi.org/10.1038/ng.2814

Article  CAS  PubMed  Google Scholar 

Ogura K, Hosoda F, Nakamura H, Hama N, Totoki Y, Yoshida A, Ohashi S, Rokutan H, Takai E, Yachida S, Kawai A, Tanaka S, Shibata T (2017) Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone. Genes Chromosomes Cancer 56:711–718. https://doi.org/10.1002/gcc.22469

Article  CAS  PubMed  Google Scholar 

Righi A, Mancini I, Gambarotti M, Picci P, Gamberi G, Marraccini C, Dei Tos AP, Simi L, Pinzani P, Franchi A (2017) Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. Hum Pathol 68:128–135. https://doi.org/10.1016/j.humpath.2017.08.033

Article  CAS  PubMed  Google Scholar 

Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, Gibbons R, Tirabosco R, O’Donnell P, Flanagan AM (2017) H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol 41:1059–1068. https://doi.org/10.1097/PAS.0000000000000859

Article  PubMed  PubMed Central  Google Scholar 

Luke J, von Baer A, Schreiber J, Lubbehusen C, Breining T, Mellert K, Marienfeld R, Schultheiss M, Moller P, Barth TFE (2017) H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology 71:125–133. https://doi.org/10.1111/his.13190

Article  PubMed  Google Scholar 

Yamamoto H, Iwasaki T, Yamada Y, Matsumoto Y, Otsuka H, Yoshimoto M, Kohashi K, Taguchi K, Yokoyama R, Nakashima Y, Oda Y (2018) Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol 73:41–50. https://doi.org/10.1016/j.humpath.2017.11.020

Article  CAS  PubMed  Google Scholar 

Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T (2018) Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. World J Surg Oncol 16:160. https://doi.org/10.1186/s12957-018-1459-6

Article  PubMed  PubMed Central  Google Scholar 

Ishihara S, Yamamoto H, Iwasaki T, Toda Y, Yamamoto T, Yoshimoto M, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I, Yamada Y, Kohashi K, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Kakuda Y, Nakashima Y, Oda Y (2022) Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation. Mod Pathol 35:640–648. https://doi.org/10.1038/s41379-021-00972-x

Article  CAS  PubMed  Google Scholar 

Yoshida KI, Nakano Y, Honda-Kitahara M, Wakai S, Motoi T, Ogura K, Sano N, Shibata T, Okuma T, Iwata S, Kawai A, Ichimura K, Yoshida A (2019) Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Mod Pathol 32:1751–1761. https://doi.org/10.1038/s41379-019-0318-5

Article  CAS  PubMed  Google Scholar 

Kato I, Furuya M, Matsuo K, Kawabata Y, Tanaka R, Ohashi K (2018) Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses. Histopathology 72:914–922. https://doi.org/10.1111/his.13448

Article  PubMed  Google Scholar 

Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, Deshpande V (2016) Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol 40:72–80. https://doi.org/10.1097/PAS.0000000000000506

Article  PubMed  Google Scholar 

Bahk WJ, Mirra JM (2015) Differential diagnostic value of “blue reticulated chondroid-like material” in aneurysmal bone cysts: a classic histopathologic analysis of 215 cases. Am J Clin Pathol 143:823–829. https://doi.org/10.1309/AJCP33YDDJKFFTSV

Article  PubMed  Google Scholar 

Amary MF, Berisha F, Mozela R, Gibbons R, Guttridge A, O’Donnell P, Baumhoer D, Tirabosco R, Flanagan AM (2016) The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology 69:121–127. https://doi.org/10.1111/his.12945

Article  PubMed  Google Scholar